rosiglitazone has been researched along with Vascular Calcification in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, X; Gu, J; He, T; Huang, Y; Liu, C; Liu, L; Liu, Y; Nie, L; Xiong, J; Xu, X; Yang, K; Yu, Y; Zhang, B; Zhang, J; Zhang, Y; Zhang, Z; Zhao, J | 1 |
| Bednarczyk, A; Boucher, P; Boudier, C; Bruban, V; Chambon, P; Chollet, ME; Coudane, F; El Asmar, Z; Foppolo, S; Herz, J; Matz, RL; Metzger, D; Mlih, M; Ninio, E; Schaeffer, C; Terrand, J; Thiersé, D; Van Dorsselaer, A; Wahli, W; Woldt, E | 1 |
2 other study(ies) available for rosiglitazone and Vascular Calcification
| Article | Year |
|---|---|
High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification.
Topics: Adolescent; Adult; Aged; Animals; Cell Line; Diet; Down-Regulation; Feeding Behavior; Female; Glucuronidase; Humans; Klotho Proteins; Methyl-CpG-Binding Protein 2; Mice; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphates; PPAR gamma; Renal Insufficiency, Chronic; RNA, Small Interfering; Rosiglitazone; Vascular Calcification; Young Adult | 2018 |
The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells.
Topics: Animals; Humans; Immunoblotting; Immunoprecipitation; In Situ Hybridization; In Vitro Techniques; Low Density Lipoprotein Receptor-Related Protein-1; Membrane Proteins; Mice; Mice, Knockout; Models, Biological; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Rosiglitazone; Thiazolidinediones; Vascular Calcification; Wnt Proteins; Wnt-5a Protein | 2012 |